Financial Snapshot

Revenue
$75.48M
TTM
Gross Margin
68.55%
TTM
Net Earnings
-$6.243M
TTM
Current Assets
$60.74M
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
99.16%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
$86.01M
Q3 2024
Book Value
$29.83M
Q3 2024
Cash
Q3 2024
P/E
-1.546
Nov 29, 2024 EST
Free Cash Flow
-$1.326M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Revenue $81.00M $107.4M $96.67M $65.63M $27.63M $7.320M $3.660M $3.222M $2.562M $261.8K $58.93K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -24.58% 11.1% 47.29% 137.52% 277.49% 100.0% 13.61% 25.72% 878.85% 344.23%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Revenue $81.00M $107.4M $96.67M $65.63M $27.63M $7.320M $3.660M $3.222M $2.562M $261.8K $58.93K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue $26.42M $40.77M $44.39M $36.43M $8.281M $2.200M $2.050M $1.417M $957.1K $88.11K
Gross Profit $54.59M $66.63M $52.28M $29.20M $19.35M $5.120M $1.610M $1.804M $1.605M $173.7K
Gross Profit Margin 67.39% 62.04% 54.08% 44.49% 70.03% 69.95% 43.99% 56.0% 62.65% 66.34%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Selling, General & Admin $49.47M $70.08M $69.88M $55.81M $31.06M $19.24M $17.73M $17.44M $8.518M $3.981M $60.00K $50.00K $60.00K $130.0K $60.00K $60.00K $60.00K $50.00K
YoY Change -29.4% 0.28% 25.22% 79.68% 61.43% 8.52% 1.65% 104.78% 113.96% 6534.96% 20.0% -16.67% -53.85% 116.67% 0.0% 0.0% 20.0%
% of Gross Profit 90.63% 105.17% 133.66% 191.12% 160.51% 375.78% 1101.24% 966.76% 530.57% 2292.22%
Research & Development $2.791M $4.095M $14.44M $5.623M $1.722M $590.0K $170.0K $959.9K $6.128M $3.219M $3.934M
YoY Change -31.84% -71.64% 156.78% 226.54% 191.86% 247.06% -82.29% -84.34% 90.34% -18.16%
% of Gross Profit 5.11% 6.15% 27.62% 19.26% 8.9% 11.52% 10.56% 53.2% 381.7% 1853.69%
Depreciation & Amortization $8.272M $8.815M $10.25M $9.201M $5.714M $2.730M $2.590M $4.365M $874.8K $118.2K $97.48K $0.00 $10.00K $10.00K $10.00K $10.00K $10.00K $10.00K
YoY Change -6.16% -14.01% 11.41% 61.03% 109.3% 5.41% -40.66% 398.94% 640.08% 21.26% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
% of Gross Profit 15.15% 13.23% 19.61% 31.51% 29.53% 53.32% 160.87% 241.91% 54.49% 68.06%
Operating Expenses $59.84M $83.70M $163.8M $88.07M $40.48M $21.97M $19.45M $23.35M $24.27M $7.200M $3.934M $50.00K $60.00K $130.0K $60.00K $60.00K $60.00K $50.00K
YoY Change -28.5% -48.92% 86.04% 117.55% 84.26% 12.96% -16.69% -3.79% 237.02% 83.05% 7767.24% -16.67% -53.85% 116.67% 0.0% 0.0% 20.0%
Operating Profit -$5.254M -$17.07M -$111.6M -$58.87M -$21.13M -$16.85M -$17.84M -$20.13M -$21.70M -$7.632M -$6.347M
YoY Change -69.21% -84.7% 89.5% 178.6% 25.41% -5.55% -11.36% -7.28% 184.37% 20.25%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Interest Expense -$8.228M $0.00 -$862.0K -$2.050M -$2.600M -$450.0K $3.230M $2.534M $5.491M $115.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% -57.95% -21.15% 477.78% -113.93% 27.45% -53.85% 4675.45%
% of Operating Profit
Other Income/Expense, Net $568.0K $14.00K $1.278M $840.0K $7.510M -$2.383M -$6.476M -$115.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 3957.14% -98.9% 52.14% -88.81% -63.2% 5531.33%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Pretax Income -$14.08M -$17.05M -$110.3M -$58.03M -$13.62M -$27.13M -$10.19M -$22.51M -$28.18M -$7.747M -$6.392M -$60.00K -$60.00K -$140.0K -$60.00K -$60.00K -$60.00K -$50.00K
YoY Change -17.45% -84.54% 90.04% 326.03% -49.79% 166.24% -54.73% -20.12% 263.74% 21.2% 10553.98% 0.0% -57.14% 133.33% 0.0% 0.0% 20.0%
Income Tax $1.768M $0.00 -$110.0K $259.0K $0.00 $0.00 $0.00 $0.00 -$23.91K -$813.7K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.84M -$17.10M -$110.2M -$58.29M -$13.62M -$27.13M -$10.19M -$22.51M -$28.18M -$7.723M -$5.579M -$60.00K -$60.00K -$140.0K -$60.00K -$60.00K -$60.00K -$50.00K
YoY Change -7.35% -84.48% 89.01% 327.93% -49.79% 166.24% -54.73% -20.13% 264.87% 38.44% 9197.82% 0.0% -57.14% 133.33% 0.0% 0.0% 20.0%
Net Earnings / Revenue -19.56% -15.92% -113.97% -88.81% -49.29% -370.63% -278.42% -698.67% -1099.73% -2950.32% -9466.8%
Basic Earnings Per Share -$2.86 -$5.11 -$3.39 -$3.48
Diluted Earnings Per Share -$2.86 -$5.11 -$3.75 -$3.481M -$3.013M -$34.78M -$145.6M -$9.660B -$64.74B -$40.26B -$6.840B -$6.858B -$7.248B -$19.60B -$10.09B -$10.12B -$9.844B -$8.905B

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Cash & Short-Term Investments $20.01M $23.00M $19.36M $49.65M $48.10M $11.00M $7.000M $800.0K $9.100M $7.400M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -13.02% 18.8% -61.01% 3.22% 337.27% 57.14% 775.0% -91.21% 22.97%
Cash & Equivalents $20.01M $23.00M $19.36M $49.65M $48.10M $11.00M $7.000M $800.0K $8.100M $7.400M
Short-Term Investments $0.00 $1.000M
Other Short-Term Assets $5.635M $8.900M $8.008M $11.07M $11.70M $1.300M $500.0K $400.0K $300.0K $500.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -36.69% 11.14% -27.66% -5.38% 800.0% 160.0% 25.0% 33.33% -40.0%
Inventory $12.63M $12.00M $10.85M $16.34M $10.00M $1.400M $1.300M $1.300M $500.0K $0.00
Prepaid Expenses
Receivables $23.62M $28.90M $21.71M $28.18M $5.600M $1.700M $600.0K $500.0K $200.0K $200.0K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $61.89M $72.80M $59.93M $105.2M $75.40M $15.40M $9.500M $3.000M $10.10M $8.000M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -14.98% 21.48% -43.05% 39.57% 389.61% 62.11% 216.67% -70.3% 26.25%
Property, Plant & Equipment $1.522M $3.900M $6.296M $8.703M $900.0K $200.0K $200.0K $600.0K $200.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -60.97% -38.06% -27.66% 867.0% 350.0% 0.0% -66.67% 200.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.229M $800.0K $766.0K $465.0K $0.00 $0.00 $0.00 $0.00 $200.0K $300.0K $0.00 $0.00
YoY Change 178.63% 4.44% 64.73% -100.0% -33.33%
Total Long-Term Assets $56.20M $63.70M $77.69M $160.4M $77.90M $19.30M $11.60M $12.00M $14.20M $10.20M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $100.0K $100.0K
YoY Change -11.77% -18.01% -51.57% 105.95% 303.63% 66.38% -3.33% -15.49% 39.22% -100.0% 0.0%
Total Assets $118.1M $136.5M $137.6M $265.7M $153.3M $34.70M $21.10M $15.00M $24.30M $18.20M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $100.0K $100.0K
YoY Change
Accounts Payable $20.40M $24.50M $10.99M $19.26M $11.80M $2.300M $2.100M $2.200M $3.500M $1.200M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -16.72% 122.99% -42.94% 63.18% 413.04% 9.52% -4.55% -37.14% 191.67%
Accrued Expenses $29.32M $37.00M $35.95M $49.49M $11.10M $2.000M $700.0K $1.100M $1.200M $200.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -20.75% 2.93% -27.36% 345.81% 455.0% 185.71% -36.36% -8.33% 500.0%
Deferred Revenue
YoY Change
Short-Term Debt $2.395M $1.600M $3.813M $7.934M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $100.0K $100.0K $100.0K $100.0K $100.0K $0.00 $0.00
YoY Change 49.69% -58.04% -51.94% -100.0% 0.0% 0.0% 0.0% 0.0%
Long-Term Debt Due $1.857M $100.0K $96.00K $16.67M $0.00
YoY Change 1757.0% 4.17% -99.42%
Total Short-Term Liabilities $62.23M $69.00M $64.44M $109.4M $28.80M $5.400M $3.400M $3.600M $10.10M $1.500M $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $0.00 $0.00
YoY Change -9.81% 7.07% -41.12% 279.99% 433.33% 58.82% -5.56% -64.36% 573.33% 1400.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Long-Term Debt $10.88M $14.70M $14.28M $180.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -26.01% 2.95% 7832.78%
Other Long-Term Liabilities $17.27M $13.40M $12.81M $18.48M $29.50M $22.30M $4.200M $7.400M $4.200M $1.100M
YoY Change 28.91% 4.61% -30.69% -37.35% 32.29% 430.95% -43.24% 76.19% 281.82%
Total Long-Term Liabilities $28.15M $28.10M $27.09M $18.66M $29.50M $22.30M $4.200M $7.400M $4.200M $1.100M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 0.18% 3.73% 45.16% -36.74% 32.29% 430.95% -43.24% 76.19% 281.82%
Total Liabilities $90.38M $97.10M $91.53M $128.1M $58.30M $27.60M $7.600M $11.00M $14.30M $2.600M $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $0.00 $0.00
YoY Change -6.92% 6.08% -28.55% 119.73% 111.23% 263.16% -30.91% -23.08% 450.0% 2500.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Basic Shares Outstanding 5.538M 3.340M 29.40M 16.75M
Diluted Shares Outstanding 3.340M 29.40M 16.75M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $9.6545 Million

About AYTU BIOPHARMA, INC

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 99 full-time employees. The company went IPO on 2017-10-20. The firm's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Industry: Pharmaceutical Preparations Peers: AGILE THERAPEUTICS INC Barrel Energy Inc. Cingulate Inc. Hoth Therapeutics, Inc. Jaguar Health, Inc. JOHNSON & JOHNSON Petros Pharmaceuticals, Inc. Pulmatrix, Inc. WEED, INC. Virpax Pharmaceuticals, Inc.